MCID: RNL018
MIFTS: 38

Renal Pelvis Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Renal Pelvis Carcinoma

MalaCards integrated aliases for Renal Pelvis Carcinoma:

Name: Renal Pelvis Carcinoma 12 15 73
Malignant Tumor of Renal Pelvis 12 73
Malignant Neoplasm of Renal Pelvis 12
Malignant Renal Pelvis Neoplasm 12
Carcinoma of Kidney Pelvis 12
Renal Pelvis Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4919
ICD10 33 C65
ICD9CM 35 189.1
NCIt 50 C6142 C7525

Summaries for Renal Pelvis Carcinoma

MalaCards based summary : Renal Pelvis Carcinoma, also known as malignant tumor of renal pelvis, is related to renal pelvis adenocarcinoma and renal pelvis transitional cell carcinoma. An important gene associated with Renal Pelvis Carcinoma is MACC1 (MACC1, MET Transcriptional Regulator), and among its related pathways/superpathways are HIF-2-alpha transcription factor network and Alpha-synuclein signaling. The drugs Docetaxel and Ramucirumab have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Renal Pelvis Carcinoma

Diseases related to Renal Pelvis Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 renal pelvis adenocarcinoma 30.6 HCK KRT19 KRT7 PAX8 SLC2A1
2 renal pelvis transitional cell carcinoma 10.9 KRT7 UPK3A
3 nephrogenic adenoma of urinary bladder 10.9 KRT7 PAX8
4 bladder benign neoplasm 10.9 KRT7 PAX8
5 ovarian benign neoplasm 10.9 KRT7 UPK3A
6 cystic basal cell carcinoma 10.8 KRT20 KRT7
7 endosalpingiosis 10.8 KRT7 PAX8
8 vaginal benign neoplasm 10.8 KRT20 KRT7
9 seminal vesicle adenocarcinoma 10.8 KRT20 KRT7
10 transverse colon cancer 10.8 KRT20 KRT7
11 appendix adenocarcinoma 10.8 KRT20 KRT7
12 ovarian large-cell neuroendocrine carcinoma 10.8 KRT20 KRT7
13 vaginal adenoma 10.8 KRT20 KRT7
14 vaginal tubulovillous adenoma 10.8 KRT20 KRT7
15 eyelid neoplasm 10.8 KRT20 KRT7
16 malignant syringoma 10.8 KRT20 KRT7
17 endocervical carcinoma 10.8 KRT7 PAX8
18 krukenberg carcinoma 10.8 KRT20 KRT7
19 large intestine adenocarcinoma 10.8 KRT20 KRT7
20 linitis plastica 10.8 KRT20 KRT7
21 lung acinar adenocarcinoma 10.8 KRT20 KRT7
22 small cell carcinoma of the bladder 10.8 KRT20 KRT7
23 adenoid squamous cell carcinoma 10.8 KRT20 KRT7
24 eccrine sweat gland neoplasm 10.8 KRT20 KRT7
25 mucinous bronchioloalveolar adenocarcinoma 10.8 KRT20 KRT7
26 bile duct cystadenocarcinoma 10.8 KRT20 KRT7
27 nephrogenic adenoma 10.8 KRT7 PAX8
28 intratubular embryonal carcinoma 10.8 KRT20 KRT7
29 urethra adenocarcinoma 10.8 PAX8 UPK3A
30 urethra clear cell adenocarcinoma 10.8 PAX8 UPK3A
31 ovarian mucinous adenocarcinoma 10.8 KRT20 KRT7
32 thymus adenocarcinoma 10.8 KRT20 KRT7
33 gastric diffuse adenocarcinoma 10.8 KRT20 KRT7
34 meibomian cyst 10.8 KRT20 KRT7
35 papillary serous adenocarcinoma 10.8 KRT20 KRT7
36 bladder adenocarcinoma 10.7 KRT20 KRT7
37 jejunal adenocarcinoma 10.7 KRT20 KRT7
38 medulloepithelioma 10.7 KRT20 KRT7
39 glycogen-rich clear cell breast carcinoma 10.7 KRT20 KRT7
40 kidney benign neoplasm 10.7 KRT7 PAX8
41 rectum adenocarcinoma 10.7 KRT20 KRT7
42 paget disease, extramammary 10.7 KRT20 KRT7
43 ampulla of vater neoplasm 10.7 KRT20 KRT7
44 appendix cancer 10.7 KRT20 KRT7
45 ampulla of vater adenocarcinoma 10.7 KRT20 KRT7
46 mucinous cystadenocarcinoma 10.7 KRT20 KRT7
47 lymphoepithelioma-like carcinoma 10.7 KRT20 KRT7
48 dermoid cyst 10.7 KRT20 KRT7
49 rete testis neoplasm 10.7 KRT20 PAX8
50 collecting duct carcinoma 10.7 KRT7 PAX8

Comorbidity relations with Renal Pelvis Carcinoma via Phenotypic Disease Network (PDN):


Bladder Cancer Deficiency Anemia
Hydronephrosis Prostatic Hypertrophy
Ureter, Cancer of

Graphical network of the top 20 diseases related to Renal Pelvis Carcinoma:



Diseases related to Renal Pelvis Carcinoma

Symptoms & Phenotypes for Renal Pelvis Carcinoma

GenomeRNAi Phenotypes related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.74 HCK
2 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.74 HCK
3 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.74 SLC2A1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.74 KRT19
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.74 SLC2A1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.74 SLC2A1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 PAX8
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 KRT19
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.74 SLC2A1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 KRT19
11 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.74 HCK
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 HCK
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.74 PAX8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.74 PAX8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.74 PAX8 SLC2A1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 HCK KRT19 PAX8 SLC2A1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.74 PAX8
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.74 HCK
19 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.74 SLC2A1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.74 SLC2A1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 PAX8
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.74 HCK

Drugs & Therapeutics for Renal Pelvis Carcinoma

Drugs for Renal Pelvis Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
2
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6 Antimitotic Agents Phase 3,Phase 2,Phase 1
7 Alkylating Agents Phase 3
8 Mitomycins Phase 3
9 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
10 Anti-Bacterial Agents Phase 3,Phase 2
11 Antibiotics, Antitubercular Phase 3,Phase 2
12 Antibodies Phase 3,Phase 2,Phase 1
13 Immunoglobulins Phase 3,Phase 2,Phase 1
14 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1
17 Antimetabolites Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 3,Phase 2,Phase 1
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
20 Mitogens Phase 3,Phase 1
21 Angiogenesis Inhibitors Phase 3
22 Angiogenesis Modulating Agents Phase 3
23 Endothelial Growth Factors Phase 3,Phase 1
24 Immunoglobulin G Phase 3
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
27
Vinblastine Approved Phase 2 865-21-4 13342 241903
28
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
29
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
30
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
32
Doxil Approved June 1999 Phase 2 31703
33 Folic Acid Antagonists Phase 2
34 Topoisomerase Inhibitors Phase 2
35 Dermatologic Agents Phase 2
36 Vitamin B Complex Phase 2
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
38 Antirheumatic Agents Phase 2
39 Antineoplastic Agents, Phytogenic Phase 2
40 Folate Nutraceutical Phase 2
41 Vitamin B9 Nutraceutical Phase 2
42
Pembrolizumab Approved Phase 1 1374853-91-4

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3 MitoGel™ instillations
2 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
3 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
4 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
5 Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Recruiting NCT02412670 Phase 2 Methotrexate;Vinblastine;Doxorubicin Hydrochloride;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
6 Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer Recruiting NCT02567409 Phase 2 ATR Kinase Inhibitor M6620;Cisplatin;Gemcitabine Hydrochloride
7 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03397394 Phase 2 Rucaparib
8 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
9 Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Active, not recruiting NCT00365157 Phase 1, Phase 2 Eribulin Mesylate
10 Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting NCT02437370 Phase 1 Pembrolizumab;Docetaxel;Gemcitabine Hydrochloride
11 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Active, not recruiting NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
12 Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer Recruiting NCT01050504

Search NIH Clinical Center for Renal Pelvis Carcinoma

Genetic Tests for Renal Pelvis Carcinoma

Anatomical Context for Renal Pelvis Carcinoma

MalaCards organs/tissues related to Renal Pelvis Carcinoma:

41
Kidney, Endothelial, Prostate, Lung, Colon

Publications for Renal Pelvis Carcinoma

Articles related to Renal Pelvis Carcinoma:

# Title Authors Year
1
Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis. ( 29715161 )
2018
2
Port-site metastasis as a primary complication following retroperitoneal laparoscopic radical resection of renal pelvis carcinoma or nephron-sparing surgery: A report of three cases and review of the literature. ( 27313720 )
2016
3
Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma. ( 24949951 )
2014
4
Renal oncocytoma and renal pelvis carcinoma: a rare coexistence of double renal tumors. ( 7801215 )
1994
5
Low dose epirubicin for hypercalcemia associated with renal pelvis carcinoma. ( 1712187 )
1991

Variations for Renal Pelvis Carcinoma

Expression for Renal Pelvis Carcinoma

Search GEO for disease gene expression data for Renal Pelvis Carcinoma.

Pathways for Renal Pelvis Carcinoma

Pathways related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.79 SLC2A1 VEGFA
2 10.66 HCK UCHL1
3 10.61 CA9 SLC2A1 VEGFA
4 10.37 HCK VEGFA

GO Terms for Renal Pelvis Carcinoma

Cellular components related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.8 KRT19 KRT20 KRT7

Biological processes related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.43 KRT19 KRT20 KRT7
2 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.16 PAX8 VEGFA
3 cornification GO:0070268 9.13 KRT19 KRT20 KRT7
4 kidney development GO:0001822 8.8 PAX8 UPK3A VEGFA

Sources for Renal Pelvis Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....